Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study

por Zhu, Di, Ma, Kun, Yang, Wei, Zhou, Hai-Feng, Shi, Qi, Ren, Jian-Wu, Xie, Yu-Guan, Liu, Sheng, Shi, Hai-Bin, Zhou, Wei-Zhong
Publicado 2022